Preliminary in vitro evaluation of anti-leukemic and antimalarial activities of pyrrolo[1,2-a]quinoxalinecarboxylic acid hydrazone derivatives
Acta Chimica Slovenica · 25.09.2026 · 73 (3) · 713-723
DOI: 10.17344/acsi.2026.9975 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Chimica Slovenica, online erschienen am 25.09.2026. Verfasst von Jean Gullion und 13 weiteren Autor:innen. Beteiligte Einrichtung: University of Bordeaux, CNRS, INSERM, ARNA, UMR 5320, U1212, F-33000 Bordeaux, France. Hauptthemen laut MEDLINE: Antimalarials, Hydrazones, Antineoplastic Agents, Quinoxalines.
Abstract (Originalsprache)
New pyrrolo[1,2-a]quinoxaline-2-carboxylic acid hydrazone derivatives were synthesized from nitroaniline using a multi-step pathway. Structure characterization of these novel substituted pyrrolo[1,2-a]quinoxaline-carboxylic acid hydrazones was achieved by using FT-IR, 1H NMR, 13C NMR, X-Ray and HRMS spectral analysis. These pyrroloquinoxaline hydrazone compounds were then evaluated in vitro for their potential on the human acute myeloid leukemia cell line MV4-11, in which (N’-pyridin-2-ylmethylene)pyrrolo[1,2-a]quinoxaline-2-carboxylic acid hydrazone 1a showed an IC50 value of 15.51 μM. Given the structural similarities between our hydrazone derivatives 1 and some recently published quinoline-type hydrazone compounds for antimalarial use, our compounds were also evaluated for their antimalarial activity. Among them, compound 1c demonstrated promising antiplasmodial activity, with an IC50 of 0.02 μM against the 3D7 strain of Plasmodium falciparum, exhibiting a selectivity index (SI) exceeding 5000 against this strain. Against the chloroquine-resistant Plasmodium falciparum W2 strain, hydrazone 1e emerged as the most potent and promising antimalarial candidate (IC50 = 0.03 μM), demonstrating a cytotoxicity to-antiprotozoal activity ratio exceeding 3333.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of Bordeaux, CNRS, INSERM, ARNA, UMR 5320, U1212, F-33000 Bordeaux, France.
- University of Bordeaux, CNRS, Bordeaux INP, ISM, UMR 5255, F-33400 Talence, France.
- University of Bordeaux, CNRS, INSERM, ARNA, UMR 5320, U1212, F-33000 Bordeaux, France; University of Bordeaux, INSERM UMR1312, BRIC, F-33076 Bordeaux, France.
- Université de Pau et des Pays de l'Adour, E2S UPPA, CNRS, IPREM UMR 5254, F-64053 Pau cedex 09, France.
- Université de Picardie Jules Verne, UFR de Pharmacie, Agents Infectieux, Résistance et Chimiothérapie (AGIR), UR 4294, F-80037 Amiens, France.
- University of Bordeaux, ICMCB-UMR 5026, F-33608 Pessac, France.
Zitieren
APA
Gullion, J., Pinaud, N., Lari, L., Ronga, L., Agnamey, P., Damiani, C., Savrimoutou, S., Si Ahmed Charrier, E., Zangmo, T., Moreau, S., Marchivie, M., Albenque, S., Desplat, V., & Sonnet, P. (2026). Preliminary in vitro evaluation of anti-leukemic and antimalarial activities of pyrrolo[1,2-a]quinoxalinecarboxylic acid hydrazone derivatives. Acta Chimica Slovenica, 73(3), 713-723. https://doi.org/10.17344/acsi.2026.9975
Vancouver
Gullion J, Pinaud N, Lari L, Ronga L, Agnamey P, Damiani C, et al. Preliminary in vitro evaluation of anti-leukemic and antimalarial activities of pyrrolo[1,2-a]quinoxalinecarboxylic acid hydrazone derivatives. Acta Chimica Slovenica. 2026;73(3):713-723. doi:10.17344/acsi.2026.9975
BibTeX
@article{Gullion2026,
author = {Gullion, Jean and Pinaud, Noel and Lari, Lindita and Ronga, Luisa and Agnamey, Patrice and Damiani, Céline and Savrimoutou, Solène and Si Ahmed Charrier, Elise and Zangmo, Tshering and Moreau, Stéphane and Marchivie, Mathieu and Albenque, Sandra and Desplat, Vanessa and Sonnet, Pascal},
title = {Preliminary in vitro evaluation of anti-leukemic and antimalarial activities of pyrrolo[1,2-a]quinoxalinecarboxylic acid hydrazone derivatives},
journal = {Acta Chimica Slovenica},
year = {2026},
volume = {73},
number = {3},
pages = {713--723},
doi = {10.17344/acsi.2026.9975}
}
EUVIMED